BRAIN, AnalytiCon Discovery and Roquette reach major milestone in DOLCE program
BRAIN, AnalytiCon Discovery and Roquette reach major milestone in DOLCE program for natural- based sugar and calorie reduction in food and beverages faster than originally expected.
- First selection of natural-based sweetening solutions identified and shared with members of the DOLCE partnership
- Food and beverage companies are now testing the sweetening solutions within their product portfolios
- DOLCE core team is currently entering into partnerships for additional product categories
The bioeconomy company BRAIN, the natural product specialist AnalytiCon Discovery GmbH and Roquette, a global leader in innovative plant-based ingredients for Food, Nutrition and Health markets – together the DOLCE core team – announced today that a major milestone has been achieved within the DOLCE partnership for next generation natural-based sweetening solutions for healthier food and beverages.
As a result of joint efforts the DOLCE core team, partners have identified and characterized first natural-based sucrose sweet taste enhancers and natural-based high intensity sweeteners. More than 25 promising candidates have been selected, faster than originally expected. These novel compounds are now shared with Consumer Product Goods Companies (CPGC), which are members of the DOLCE partnership. These members are allowed to test the natural-based sweetening solutions within their specific product matrixes for their own food and beverage product portfolio with the goal to secure the best naturally sweet solutions.
Providing next generation sweetening solutions to the market is the goal of the DOLCE partnership which started in August 2016. Since November 2016, significant product categories were selected by active members. The DOLCE core team is currently entering into further partnerships for available product categories, and active negotiations with potential new members are ongoing.
Sergio Neves, Head of Nutrition and Health R&D at Roquette Group, says: “We are pleased, that the DOLCE program runs very well and is on track. Having identified the first selection of natural-based sweetening solutions for members of our partnership in such a short timeframe, is a significant milestone for the DOLCE program.”
Martin Langer, Unit Head Corporate Development at BRAIN, adds: “The selected all-natural development candidates have demonstrated outstanding properties and efficacy in our application tests. We continue to invite further CPGCs to join our ongoing successful DOLCE program.”
Lutz Müller-Kuhrt, CEO at AnalytiCon Discovery concludes: “The progress of DOLCE has been enabled through its first-class technology platform utilizing nature’s sweet offerings through a strong research and development partnership. First milestones are encouraging the DOLCE core team to continue its mission to find novel, natural-based, commercially viable sweet solutions for the entire food and beverage industry.”
DOLCE Partnership for novel natural-based Sweetening Solutions
For additional information on joining the DOLCE program, please contact:
Dr. Martin Langer, BRAIN AG, Executive Vice President Corporate Development,
Tel.: +49-6251-9331-16, E-Mail: email@example.com
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this „Toolbox of Nature” are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN’s business model is based on two pillars – BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN’s own products and active product components. Further information is available at www.brain-biotech.de/en.
About AnalytiCon Discovery
AnalytiCon Discovery GmbH is a global market leader in the area of compound libraries containing fully analyzed structures. Located on the Potsdam Biotech Campus, the company offers services for every stage of the supply chain for natural product-based (NP-based) substance discoveries and developments. Innovative technology concepts enable high-grade partnerships with globally operating companies from the pharmaceutical, food manufacturing and cosmetics industries. AnalytiCon Discovery enjoys access to around 15 percent of all natural compounds known worldwide, as well as to thousands of structures that have not yet been published. AnalytiCon Discovery has been a member of the BRAIN Group since 2013. Further information is available at www.ac-discovery.com www.ac-discovery.com.
About Roquette: “Offering the best of Nature”
Roquette is a global leader in plant-based ingredients and a pioneer of new vegetal proteins. In collaboration with its customers and partners, the Group addresses current and future societal challenges by unlocking the potential of Nature to offer the best ingredients for Food, Nutrition and Health markets. Each of these ingredients responds to unique and essential needs, and they enable healthier lifestyles. Thanks to a constant drive for innovation and a long-term vision, the Group is committed to improving the well-being of millions of people all over the world while taking care of resources and territories. Roquette currently operates in over 100 countries, has a turnover of around 3.2 billion euros and employs 8,300 people worldwide. Further information is available at www.roquette.com.
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.